AngioDynamics, Inc. (ANGO) Financial Ratios
24 years of historical data (2002–2025) · Healthcare · Medical - Instruments & Supplies
EV/EBITDA
N/A
—
5yr avg: 877.81
30Y Low9.4·High90.0
P/FCF
N/A
—
5yr avg: 46.89
30Y Low10.5·High161.3
P/B Ratio
↑
2.48
↑+49% vs avg
5yr avg: 1.67
30Y Low0.6·High5.0
ROE
↓
-17.5%
↓+18% vs avg
5yr avg: -21.4%
30Y Low-63%·High199%
Debt/EBITDA
N/A
—
5yr avg: 38.48
30Y Low0.2·High38.5
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ANGO Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
AngioDynamics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $459M | $418M | $254M | $373M | $766M | $886M | $388M | $704M | $789M | $557M | $434M |
| Enterprise Value | $404M | $362M | $182M | $393M | $771M | $858M | $374M | $613M | $809M | $616M | $535M |
| P/E Ratio → | -13.31 | — | — | — | — | — | — | 11.46 | 47.80 | 79.37 | — |
| P/S Ratio | 1.57 | 1.43 | 0.83 | 1.10 | 2.42 | 3.05 | 1.47 | 1.96 | 2.29 | 1.59 | 1.23 |
| P/B Ratio | 2.48 | 2.28 | 1.23 | 0.99 | 1.80 | 2.02 | 0.85 | 1.15 | 1.45 | 1.08 | 0.86 |
| P/FCF | — | — | — | — | — | 46.89 | — | 20.52 | 20.98 | 10.57 | 10.96 |
| P/OCF | — | — | — | 4788.26 | — | 36.79 | — | 18.81 | 19.12 | 10.00 | 9.60 |
P/E links to full P/E history page with 30-year chart
ANGO EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.24 | 0.60 | 1.16 | 2.44 | 2.95 | 1.42 | 1.71 | 2.35 | 1.76 | 1.51 |
| EV / EBITDA | — | — | — | — | 877.81 | — | — | 37.20 | 89.97 | 45.16 | 18.38 |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | 4056.22 |
| EV / FCF | — | — | — | — | — | 45.40 | — | 17.87 | 21.50 | 11.67 | 13.51 |
ANGO Profitability
Margins and return-on-capital ratios measuring operating efficiency
AngioDynamics, Inc. earns an operating margin of -13.7%. Operating margins have expanded from -15.1% to -13.7% over the past 3 years, signaling improving operational efficiency. A negative ROE of -17.5% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 53.9% | 53.9% | 50.9% | 51.4% | 52.4% | 53.9% | 56.9% | 43.4% | 41.8% | 41.2% | 49.3% |
| Operating Margin | -13.7% | -13.7% | -63.3% | -15.1% | -9.0% | -12.1% | -63.3% | -2.6% | -4.1% | -3.2% | 0.3% |
| Net Profit Margin | -11.6% | -11.6% | -60.7% | -15.5% | -8.4% | -10.8% | -63.1% | 17.1% | 4.7% | -2.0% | -12.3% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -17.5% | -17.5% | -63.1% | -13.1% | -6.1% | -7.0% | -31.2% | 10.6% | 3.1% | -1.4% | -8.3% |
| ROA | -11.4% | -11.4% | -43.4% | -9.7% | -4.8% | -5.5% | -23.3% | 8.0% | 2.3% | -1.0% | -5.8% |
| ROIC | -22.9% | -22.9% | -54.2% | -9.3% | -5.1% | -6.2% | -25.9% | -1.3% | -1.9% | -1.4% | 0.1% |
| ROCE | -18.6% | -18.6% | -57.0% | -11.0% | -5.8% | -6.7% | -25.6% | -1.3% | -2.2% | -1.7% | 0.1% |
ANGO Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $56M exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.02 | 0.17 | 0.08 | 0.05 | 0.09 | 0.22 | 0.17 | 0.20 | 0.26 |
| Debt / EBITDA | — | — | — | — | 38.48 | — | — | 8.28 | 10.42 | 7.77 | 4.58 |
| Net Debt / Equity | — | -0.31 | -0.35 | 0.05 | 0.01 | -0.06 | -0.03 | -0.15 | 0.04 | 0.11 | 0.20 |
| Net Debt / EBITDA | — | — | — | — | 5.65 | — | — | -5.53 | 2.18 | 4.28 | 3.47 |
| Debt / FCF | — | — | — | — | — | -1.49 | — | -2.65 | 0.52 | 1.11 | 2.55 |
| Interest Coverage | — | — | — | -18.94 | -41.38 | -40.98 | -184.23 | -1.84 | -4.63 | -3.94 | 0.30 |
Net cash position: cash ($56M) exceeds total debt ($0)
ANGO Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
AngioDynamics, Inc.'s current ratio of 2.21x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 1.40x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 1.95x to 2.21x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.21 | 2.21 | 2.12 | 1.95 | 1.93 | 2.45 | 2.97 | 4.30 | 2.93 | 2.21 | 2.18 |
| Quick Ratio | 1.40 | 1.40 | 1.46 | 1.29 | 1.24 | 1.60 | 1.80 | 3.75 | 2.25 | 1.43 | 1.35 |
| Cash Ratio | 0.73 | 0.73 | 0.83 | 0.53 | 0.39 | 0.84 | 1.06 | 3.11 | 1.32 | 0.70 | 0.51 |
| Asset Turnover | — | 1.04 | 0.96 | 0.64 | 0.57 | 0.52 | 0.44 | 0.43 | 0.49 | 0.49 | 0.49 |
| Inventory Turnover | 2.17 | 2.17 | 2.46 | 2.97 | 2.93 | 2.76 | 1.90 | 2.86 | 3.00 | 2.31 | 3.24 |
| Days Sales Outstanding | — | 53.83 | 60.06 | 56.92 | 65.21 | 46.80 | 47.22 | 44.25 | 41.77 | 48.40 | 54.56 |
ANGO Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
AngioDynamics, Inc. returns 0.4% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | 8.7% | 2.1% | 1.3% | — |
| FCF Yield | — | — | — | — | — | 2.1% | — | 4.9% | 4.8% | 9.5% | 9.1% |
| Buyback Yield | 0.4% | 0.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 2.4% | 0.0% |
| Total Shareholder Yield | 0.4% | 0.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 2.4% | 0.0% |
| Shares Outstanding | — | $41M | $40M | $39M | $39M | $38M | $38M | $37M | $38M | $37M | $36M |
Peer Comparison
Compare ANGO with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ANGOYou | $459M | -13.3 | — | — | 53.9% | -13.7% | -17.5% | -22.9% | — |
 NVCR | $2B | -13.5 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 ATRC | $1B | -116.7 | 78.4 | 29.4 | 74.4% | -0.6% | -2.4% | -0.6% | 5.2 |
 MMSI | $4B | 28.9 | 12.9 | 17.0 | 48.7% | 12.2% | 8.7% | 7.2% | 2.8 |
 ITGR | $3B | 29.9 | 13.0 | 28.2 | 23.1% | 11.3% | 6.1% | 5.4% | 4.2 |
 CNMD | $1B | 24.7 | 10.1 | 7.6 | 52.8% | 10.3% | 4.7% | 5.8% | 4.3 |
 BSX | $83B | 28.9 | 25.1 | 22.8 | 69.0% | 19.8% | 12.4% | 8.8% | 3.3 |
 BDX | $52B | 24.8 | 14.0 | 19.6 | 45.4% | 11.8% | 6.5% | 4.3% | 3.8 |
 TMDX | $3B | 15.0 | 18.4 | 18.9 | 59.9% | 17.9% | 54.2% | 18.8% | 3.5 |
 MDT | $99B | 21.5 | 14.3 | 19.2 | 65.3% | 17.8% | 9.4% | 6.0% | 3.2 |
 ABT | $150B | 11.3 | 15.7 | 23.6 | 50.8% | 16.3% | 30.9% | 9.9% | 1.5 |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 24 years · Updated daily
See ANGO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ANGO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ANGO vs NVCR
Side-by-side business, growth, and profitability comparison vs NovoCure Limited.
Start ComparisonANGO — Frequently Asked Questions
Quick answers to the most common questions about buying ANGO stock.
What is AngioDynamics, Inc.'s P/E ratio?
AngioDynamics, Inc.'s current P/E ratio is -13.3x. The historical average is 53.6x.
What is AngioDynamics, Inc.'s ROE?
AngioDynamics, Inc.'s return on equity (ROE) is -17.5%. The historical average is 4.6%.
Is ANGO stock overvalued?
Based on historical data, AngioDynamics, Inc. is trading at a P/E of -13.3x. Compare with industry peers and growth rates for a complete picture.
What are AngioDynamics, Inc.'s profit margins?
AngioDynamics, Inc. has 53.9% gross margin and -13.7% operating margin.